Prevalence of osteoporosis and vitamin D receptor gene polymorphisms (FokI) in an Iranian general population based study (Kurdistan) (IMOS)

Zahra Mohammadi¹, Abbasali Keshtkar², Fateme Fayyazbakhsh³, Mehdi Ebrahimi⁴ Mahsa M Amoli^{*5}, Mostafa Ghorbani⁶, Patricia Khashayar⁷, Mahboubeh Dini⁸ Mina Ebrahimi-Rad⁹, Bagher Larijani¹⁰

Received: 24 February 2015

Accepted: 9 June 2015

Published: 20 July 2015

Abstract

Background: Osteoporosis, or porous bone, is a disease characterized by low bone mass density (BMD) and structural deterioration of bone tissue, leading to bone fragility and increased risk of hip, spine, and wrist fractures. There are numerous risk factors for osteoporosis. While many of these factors are non-genetic in nature, there is a definite genetic component responsible for this condition. The main aim of this study was to evaluate the association between VDR (Vitamin D receptor gene) polymorphisms (Fok1) A>G (rs2228570) and bone mineral density in an Iranian defined population.

Methods: The study participants comprised of 1032 Iranians recruited from the city of Sanandaj during IMOS (Iranian Multi Center Osteoporosis Study). Bone mineral density measurement was performed in all the participants with and without osteoporosis. All samples were genotyped for VDR genes (Fok1) polymorphism with polymerase chain reaction, using a predesigned TaqMan allele discrimination assay.

Results: There was a significant association between Fok1 polymorphism and osteoporosis in postmenopausal women, 0.138 (0.025-0.768).

Conclusion: It seems that cohort studies, which are more powerful than case-control studies, can be useful in evaluating the roles of genetic variants as risk or protective factors for osteoporosis.

Keywords: Osteoporosis; Vitamin D Receptor Gene; Fok1; Bone Mineral Density.

Cite this article as: Mohammadi Z, Keshtkar A, Fayyazbakhsh F, Ebrahimi M, Amoli MM, Ghorbani M, Khashayar P, Dini M, Ebrahimi-Rad M, Larijani B. Prevalence of osteoporosis and vitamin D receptor gene polymorphisms (FokI) in an Iranian general population based study (Kurdistan) (IMOS). *Med J Islam Repub Iran* 2015 (20 July). Vol. 29:238.

Introduction

Osteoporosis is a metabolic bone disease, characterized by low bone mass and bone tissue deterioration, which leads to osteoporotic fracture risk (1,2). It is a disease

caused by the interaction of genetic and environmental factors. According to many studies, the contribution of genetic and environmental factors is about 70% and 30%, respectively. The environmental factors;

¹. MSc in Genetics, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Mimina_13@yahoo.com

². MD, PhD in Epidemiology, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. abkeshtkar@gmail.com

 ³. PhD Student in Biomaterials Medical Engineer, Biomedical Engineering Department, Maziar University, Rouyan, Iran. F.fba.te@gmail.com
⁴. MD, Endocrinologist, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. M ebrahimi49@yahoo.com

⁵. (**Corresponding author**) MD, PhD in Immune Genetics, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. mahsaamoli@hotmail.com

⁶. PhD in Epidemiology, Alborz University of Medical Sciences, Karaj, Iran. mqorbani1379@yahoo.com

⁷. PhD Student in Bio Nanotechnology, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Patricia.kh@gmail.com

⁸. MD, MPH, Non-communicable Disease Department, Iran Ministry of Health and Medical Education, Tehran, Iran. drmahdin@yahoo.com.

⁹. PhD in Biochemistry, Biochemistry Department, Pasteur Institute of Iran, Tehran, Iran. minebrad@yahoo.com

¹⁰. MD, Endocrinologist, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

however, can control gene expression and the process of the disease (3).

In this regard, several studies have focused on the influence of ethnicity on bone mineral density (BMD) and osteoporosis. About 60% of the bone characteristics are genetic-dependent; the Caucasians and Asians usually have lower bone density than the Negros, Hispanics and Latino Americans (4-6).

Different genes are reported to be linked with osteoporosis, the most important of which is vitamin D receptor gene (VDR) (7). The most common genetic markers that have been investigated in genetic association studies of BMD or osteoporosis are the single nucleotide polymorphisms (SNPs) in the VDR gene (8).

VDR, expressed in certain organs, has a vital role in calcium homeostasis. VDR repress proximal activator of 1, 25 (OH) 2 D3, inducing the expression of 1, 25(OH) 2 D3 through deactivating the enzyme CYP24 (1,25-dihydroxyvitamin D3 24-hydroxylase, mitochondrial) (9).

The human VDR gene is localized on chromosome 12q12-q14 (10). There are more than 100 restriction endonuclease recognition sites in VDR gene such as Fok1, Bsm1, Apa1 and etc. Fok1 is located on exon 2 (11-13). VDR genotypes are associated with the development of several bone diseases as well as osteoporosis and other complex maladies such as osteoarthritis and diabetes (14).

Several studies have evaluated the relationship between VDR polymorphism and BMD. There are controversial reports regarding the relationship between Fok1 and BMD values (15-19). Previous studies have investigated the frequency of Fok1 genotypes and its relationship with BMD or osteoporosis in the Iranian population. However, the results were controversial indicating the necessity of conducting a more comprehensive population based study with a larger sample size (20-23).

The aim of this study was to analyze the association between the Fok1 polymorphism and BMD values in a large group of

Iranians from a defined population of Sanandaj, the twenty-third largest city in Iran and also the capital of Kurdistan Province (24).

Methods

The Iranian Multi Center Osteoporosis Study (IMOS) was conducted on an Iranian population in three phases. The third phase was performed in two big cities in 2012-2013. All individuals older than 20 years of age were selected using random cluster sampling. We excluded cases with metabolic bone disease, or those taking any medication known to affect bone metabolism such as any kinds of vitamin D. Cases suffering from cancer, acute or chronic renal failure, or advanced liver failure were also excluded.

Participants

In this study, 1032 Iranians recruited from Sanandaj city during IMOS were included in this study. They were classified into 3 groups according to the World Health Organization (WHO) criteria, and based on BMD measurements at the lumbar (L2-L4) spine, Hip and femoral neck. BMD measurements were performed by dualenergy X-ray absorptiometry (Norland XR46) following manufacturer protocols. A structured questionnaire assessing biological and lifestyle risk factors was completed by each participant; informed consent was obtained from all the participants, and all were subject to full history taking, clinical examination and laboratory investigations. The protocol was approved by the Ethics Committee of Tehran University of Medical Sciences.

Genotyping

Genomic DNA was isolated from peripheral blood leukocytes, and DNA extraction was performed using the phenol chloroform method (25). The VDR SNPs, Fok1 A>G (rs2228570) were genotyped using a Taq-Man 5'-exonuclease SNP allelic discrimination assay with the ABI 7300 Real-Time PCR System (Applied Biosystems, Foster

City, CA, USA). Negative and positive controls were included to ensure the accuracy of genotyping. The reactions were carried out in a total volume of 15 μ L containing 50 ng DNA. The thermal cycler conditions consisted of an initial hold for 10 min at 95°C, followed by 40 cycles of 15 s at 92°C, and 1 min at 60°C each.

Statistical Analysis

STATA program version 11.0 was used for data analysis. Data were summarized as mean, SD. One way ANOVA was done to analyze more than two variables, followed by post hoc test to detect the significance. Logistic regression analysis was used to assess the association of Fok1polymorphism and BMD. The crude association was assessed in model 1, and the association was adjusted for BMI and age in model II. P-value was considered significant at <0.05.

In this study, because of the importance of age and sex in osteoporosis diagnosis, the participants were divided in four categories based on their age and gender: men younger than 50 years of age, men equal and older than 50 years, pre and postmenopausal women.

Results

Baseline characteristics of the participants are illustrated in Table 1. Overall, 61%

(n=629) of the participants were female. The mean \pm SD age of post-menopausal women was 49.4 \pm 4.05 years.

In total, 11.8% (n= 122) of the participants suffered from osteoporosis. The prevalence of osteoporosis in men over 50 years of age and postmenopausal women was 44.1% and 37%, respectively; and the difference was significant (p < 0.001).

The prevalence of Vitamin D deficiency was 85.1%, and the condition was reported in 92.7%, 81.1%, 85.9% and 73.5% of men younger than 50 years, men over 50 years, pre-menopausal and postmenopausal women, respectively. A significant difference was found between the four groups (p<0.001).

There was a significant relationship between age-sex groups and BMD values at all bone sites, osteoporosis, BMI, height, weight, Vitamin D and calcium (p<0.0001).

Age, Vitamin D serum level, and calcium were significantly different between osteoporotic and non-osteoporotic groups (p<0.05).

The frequency of Fok1 genotypes according to osteoporotic and non-osteoporotic subjects are presented in Table 2. The frequencies of FF, Ff and ff genotypes in participants were 55.5%, 38.3% and 6.2%, respectively.

The frequency of genotypes in osteoporotic and non-osteoporotic group was sig-

Table 1. Baseline	Characteristics of th	e Participants	Based On Ag	e-Sex Groups:	The IMOS Study	in Sanandai

Characteristics	Men<50 Yr	Men≥50 Yr	Premenopausal	Postmenopausal	Total
			women	women	
Number	268	134	458	172	1032
Age(Yr)	32.9±8.60	61.2 ± 8.90	35.4±9.	58.1±7.90	41.9±14.62
Height(cm)	172.4±6.85	166.9±7.19	156.9 ± 5.92	154.02 ± 5.80	161.7±9.67
Weight(kg)	75.9±12.75	73.5±12.60	68.0±12.09	69.3±11.10	70.9±12.75
$BMI(kg/m^2)$	25.5±4.01	26.3±3.90	27.7±4.92	29.2±4.6	27.2±4.70
BMD L2-L4(g/cm^2)	0.98±0.150	0.91±0.150	0.99±0.1	0.83 ± 0.150	0.95±0.16
BMD Femoral Neck (g/cm ²)	0.93±0.150	0.81±0.1	0.88±0.130	0.77±0.130	0.87±0.15
BMD Hip(g/cm^2)	0.97±0.150	0.90 ± 0.1	0.92±0.130	0.82 ± 0.150	0.92 ± 0.14
Osteoporosis	75(17.4)	112(26)	101(23.5)	142(33.0)	430(100)
Non Osteoporosis	195(31.3)	24(3.8)	374(59.9)	31(5.0)	624(100)
Vitamin D (nmol/L)	29.5±16.40	43.8±69.	28.2±32.40	42.9±48.20	33.0±39.90
Calcium (mg/dL)	9.7±0.60	9.4±0.	9.5±0.60	9.6±0.60	9.5±0.60
Phosphor(mg/dL)	4.0±0.70	3.7±0.	3.9±0.60	4.1±0.60	3.9±0.70
Alkaline phosphates(U/L)	190.5±56.20	187.0±52.	165.6±54.90	205.8±64.10	181.5 ± 58.50
Bone specific Alkaline phos-	17.8±9.70	14.1±5.	13.6±10.25	17.7±8.10	15.4±9.50
phates(U/L)					
Parathyroid hormone(pg/mL)	2.4±1.20	3.0±2.0	3.0±1.70	3.2 ± 1.90	2.9±1.70

Prevalence of osteoporosis and vitamin D receptor gene polymorphisms ...

Groups	Types	FF	Ff	Ff	р
		No (%)	No (%)	No (%)	
Postmenopausal women	Osteoporotic	80(57.6)	3(2.2)	56(40.2)	0.02*
-	Non Osteoporotic	11(35.5)	3(9.7)	17(54.8)	
Premenopausal women	Osteoporotic	52(54.2)	8(8.3)	36(37.5)	0.90
*	Non Osteoporotic	198(55.6)	30(8.4)	128(36.0)	
Men<50 Yr	Osteoporotic	40(58.0)	3(4.3)	26(37.7)	0.90
	Non Osteoporotic	111(57.5)	9(4.7)	73(37.8)	
Men≥50 Yr	Osteoporotic	64(58.7)	4(3.7)	41(37.6)	0.90
	Non Osteoporotic	12(56.5)	1(4.5)	9(40.9)	

*significant

Table 3. Association of Fok1 Genotypes with Osteoporosis according to Different Age-Sex Groups
--

Model	FF	ff	Ff
	OR (CI95%)	OR (CI95%)	OR (CI95%)
Model 1	1	0.138(0.025-0.768)*	0.453(0.197-1.041)
Model 2	1	0.136(0.023-0.810)*	0.513(0.211-1.244)
Model 1	1	1.015(0.439-2.346)	1.071(0.663-1.730)
Model 2	1	1.115(0.466-2.672)	1.078(0.652-1.783)
Model 1	1	0.925(0.238-3.589)	0.988(0.556-1.757)
Model 2	1	1.320(0.328-5.302)	0.920(0.509-1.662)
Model 1	1	0.750(0.077-7.306)	0.854(0.331-2.206)
Model 2	1	0.860(0.087-8.536)	0.745(0.274-2.026)
	Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1	OR (CI95%)Model 11Model 21Model 11Model 21Model 11Model 21Model 11	OR (CI95%)OR (CI95%)Model 110.138(0.025-0.768)*Model 210.136(0.023-0.810)*Model 111.015(0.439-2.346)Model 211.115(0.466-2.672)Model 110.925(0.238-3.589)Model 211.320(0.328-5.302)Model 110.750(0.077-7.306)

Model 1: Crude model

Model 2: Adjusted for BMI and Age

*significant relationship

nificantly different in post-menopausal women (p=0.02).

Results of the logistic regression analysis on the association of Fok1 polymorphisms and osteoporosis are presented in Table 3. There was a significant association between osteoporosis and types of Fok1 polymorphisms in postmenopausal women in the crude and adjusted model. The regression analyses have shown that ff has a protective effect on osteoporosis. The possibility of osteoporosis in participants with ff genotype was 87% lower than others.

No significant relationship was found between BMD and types of Fok1 genotypes in men and premenopausal women.

Discussion

Bone is a metabolically active tissue that experiences continuous remodeling via two reciprocal processes, bone formation and resorption. Osteoclasts, osteoblasts and osteocytes are respectively responsible for bone resorption, formation and maintenance. In osteoporosis, bone density decreases due to the high activity of osteoclasts (26). The prevalence of osteoporosis is different in various ethnicities and thus it is different in multiethnic countries (27,28).

The etiology of osteoporosis is still unknown; however, the importance of age, gene-environment interactions, gene-gene interactions and life-style in the development of osteoporosis has been shown in many studies. Several lines of evidence support the involvement of genetic factors in the development of osteoporosis. These studies show that daughters of women with osteoporosis have lower bone mass than other women of the same age. The sons of men with idiopathic osteoporosis also have lower bone density in comparison with normal men (5,6). Twin research and human genetics studies have shown that osteoporosis and its outcomes are highly heritable (31-34). Animal and human studies have shown that genes can affect bone density in various pathways. The most prominent pathway is related to the exertion of calcium (35,36). The majority of these researches focus on VDR gene and the fact that single point polymorphism in this gene is known to alter metabolic activity of the bone (29).

Several studies have evaluated the association between polymorphisms of vitamin D receptor gene (Fok1, Bsm1, Taq1, Apa1) and low bone mass density or osteoporosis

(37,38).

A systematic review published in 2014 revealed a significant association between the two polymorphisms (Fok1 and Bsm1) and osteoporosis in more than 50% of the available studies. Based on the articles, 60.0% of these studies reported a significant correlation between Fok1 and higher osteoporosis risk (39). They concluded that ethnicity and race, like gender, can influence the risk of osteoporosis and BMD.

In our study, the proportions of Fok1 genotypes were not significantly different in the two genders (p=0.1). This study found that the frequency of FF. Ff and ff genotypes is 55.5%, 38.3% and 6.2% in the studied population, respectively. Similar to the study performed by Hossein-Nezhad in 2009, FF (56.5%) is the most common genotype in the Iranian population (21). As for the Indian population, FF was seen in 59%, Ff in 36%, and ff in 5% of the studied population (40). In the Lampedusa Italian population, the observed proportions of Fok1 genotypes were 33.2% for FF, 32.8% for Ff, and 34% for ff (41). In the Spanish population, the prevalence of these genotypes was 40.4, 48.0 and 11.6% for FF, Ff and ff, correspondingly (42).

In the present study, BMD values in all the participants at either site were higher in ff genotype although the difference did not reach statistical significance. However, in this study, post-menopausal women with ff genotype exhibited a significantly lower risk for osteoporosis, compared with those with Ff and FF genotypes. Other investigators have reported that women with ff genotype experience greater bone loss at hip when compared with those with either Ff or FF genotypes (43-44). The previous studies conducted on Iranian population have shown that participants with ff genotype exhibited a significantly lower hip bone mass (21). Based on Hossein-Nezhad's study, individuals with ff genotype have a significantly lower bone mass at lumbar spine, relative to those with Ff and FF genotypes in pre- and post- menopausal women(45).

As articles have indicated, the results are vice versa. Existing literatures in this regard have shown controversial results and thus have failed to confirm the effect of Fok1 genotypes on bone mass density. However, most studies have shown the effect of confounding factors in accuracy of these results. Conducting a cohort study together with performing a cross-sectional analysis may be a more suitable observational research design for analyzing the genetic markers as risk factors for osteoporosis.

Cohort is perhaps the best-known type of observational controlled research to overcome these deficiencies. Considering the cross-sectional nature of the study and the influential role of environmental factors in the development of osteoporosis, it was not possible to confirm the role of genetic variants as risk or protective factors for osteoporosis. The present study is the first such research to be conducted on a large sample size of both genders.

Conclusion

In addition to the increasing prevalence of osteoporosis, a surge is also noted in the mortality rate of osteoporotic patients (30). The finding of this report indicated that Fok1 in VDR gene may affect bone mass and predict osteoporosis. In this study, ff genotype was a protective factor just in post-menopausal women. These findings may be useful for better management of osteoporotic patients.

Acknowledgements

We would like to thank all participants of the study. This study was supported by Iranian Ministry of Health and Medical Education and the Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences.

References

^{1.} Kelly P, Eisman J, Sambrook P. Interaction of genetic and environmental influences on peak bone density. Osteoporosis international 1990;1:56-60.

2. Pollitzer WS, Anderson JJ. Ethnic and genetic differences in bone mass: a review with a hereditary vs environmental perspective. The American journal of clinical nutrition 1989;50:1244-59.

3. Ferrari S. Osteoporosis: a complex disorder of aging with multiple genetic and environmental determinants. World review of nutrition and dietetics 2005;95:35.

4. Labinson P, Taxel P, Gagel RF, Hoff AO. National Osteoporosis Foundation. 2006.

5. van Leeuwen JP, Uitterlinden AG, Birkenhäger JC, Pols HA. Vitamin D receptor gene polymorphisms and osteoporosis. Steroids 1996; 61:154-6.

6. Van Pottelbergh I, Goemaere S, Zmierczak H, De Bacquer D, Kaufman J. Deficient Acquisition of Bone During Maturation Underlies Idiopathic Osteoporosis in Men: Evidence From a Three-Generation Family Study. Journal of Bone and Mineral Research 2003;18:303-11.

7. Hustmyer FG, Peacock M, Hui S, Johnston C, Christian J. Bone mineral density in relation to polymorphism at the vitamin D receptor gene locus. Journal of Clinical Investigation 1994;94:2130.

8. Uitterlinden AG, Pols HA, Burger H, Huang Q, van Daele PL, van Duijn CM, et al. A large-scale population-based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. Journal of Bone and Mineral Research 1996;11:1241-8.

9. Nejentsev S, Godfrey L, Snook H, Rance H, Nutland S, Walker NM, et al. Comparative highresolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Human Molecular Genetics 2004;13:1633-9.

10. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, et al. Vitamin D-related genes, serum vitamin D concentrations, and prostate cancer risk. Carcinogenesis 2009:bgp055.

11. Bai Y, Yu Y, Yu B, Ge J, Ji J, Lu H, et al. Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC medical genetics 2009;10:125.

12. Ferrari S, Rizzoli R, Chevalley T, Eisman J, Bonjour J, Slosman D. Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. The Lancet 1995;345:423-4.

13. Shahbazi S, Alavi S, Majidzadeh AK, GhaffarPour M, Soleimani A, Mahdian R. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Medical Oncology 2013;30:1-6.

14. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Experimental biology and medicine 2004;229:1136-42.

15. Arai H, Miyamoto KI, Taketani Y, Yamamoto H, Iemori Y, Morita K, et al. A vitamin D receptor gene polymorphism in the translation initiation

codon: effect on protein activity and relation to bone mineral density in Japanese women. Journal of Bone and Mineral Research 1997;12:915-21.

16. Harris SS, Eccleshall T, Gross C, Dawson-Hughes B, Feldman D. The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. Journal of Bone and Mineral Research 1997;12:1043-8.

17. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal mexican-American women. Journal of Bone and Mineral Research 1996;11:1850-5.

18. Ferrari S, Rizzoli R, Manen D, Slosman D, Bonjour JP. Vitamin D Receptor Gene Start Codon Polymorphisms (FokI) and Bone Mineral Density: Interaction with Age, Dietary Calcium, and 3'-End Region Polymorphisms. Journal of Bone and Mineral Research 1998;13:925-30.

19. Eccleshall TR, Garnero P, Gross C, Delmas PD, Feldman D. Lack of correlation between start codon polymorphism of the vitamin D receptor gene and bone mineral density in premenopausal French women: the OFELY study. Journal of Bone and Mineral Research 1998;13:31-5.

20. Ahangari G, Hossein-Nezhad A, Behzadi H, Maghbooli Z, Larijani B. Vitamin D Receptor gene polymorphism may predict response to vitamin D intake and bone turnover. DARU Journal of Pharmaceutical Sciences 2010;17:13-9.

21. Hossein-Nezhad A, Ahangari G, Larijani B. Evaluating of VDR gene variation and its interaction with Immune Regulatory Molecules in Osteoporosis. Iranian journal of public health 2009; 38:27-36.

22. Hosseinpanah F, Daneshpour MS, Ahmadi N, Behnami SP, Azizi F. Vitamin D Receptor Gene Polymorphism and Bone Mineral Density in Iranian Menopausal and Postmenopausal Women. 2014.

23. Pouresmaeili F, Jamshidi J, Azargashb E, Samangouee S. Association between vitamin D receptor gene BsmI polymorphism and bone mineral density in a population of 146 Iranian women. Cell Journal (Yakhteh) 2013;15:75.

24. Census of the Islamic Republic of Iran, 1385 (2006) (Excel). Islamic Republic of Iran. Archived from the original on 2011-11-11.

25. Zumbo P, Mason CE. Methods for RNA Isolation, Characterization and Sequencing (RNA-Seq). Genome Analysis: Current Procedures and Applications 2014:21.

26. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis 1. Endocrine reviews 2000;21:115-37.

27. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and

Downloaded from mjiri.iums.ac.ir on 2025-08-31

fracture risk in women of different ethnic groups. Journal of Bone and Mineral Research 2005;20:185-94.

28. Looker AC, Orwoll ES, Johnston CC, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older US adults from NHANES III. Journal of Bone and Mineral Research 1997;12:1761-8.

29. Rizzoli R, Bonjour J, Ferrari S. Osteoporosis, genetics and hormones. Journal of molecular endocrinology 2001;26:79-94.

30. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. Journal of bone and mineral research 2007;22:465-75.

31. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC. Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. Journal of bone and mineral research 1991;6:561-7.

32. Nguyen T, Howard G, Kelly P, Eisman JA. Bone mass, lean mass, and fat mass: same genes or same environments? American journal of epidemiology 1998;147:3-16.

33. Harris M, Nguyen T, Howard G, Kelly P, Eisman J. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone 1998;22:141-5.

34. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. Journal of Clinical Investigation 1987;80:706.

35. Williams F, Spector T. Recent advances in the genetics of osteoporosis. Journal of Musculoskeletal and Neuronal Interactions 2006;6:27.

36. Deng HW, Chen WM, Recker S, Stegman MR, Li JL, Davies KM, et al. Genetic determination of Colles' fracture and differential bone mass in women with and without Colles' fracture. Journal of Bone and Mineral Research 2000;15:1243-52.

37. Eisman JA. Vitamin D receptor gene alleles and osteoporosis: an affirmative view. Journal of Bone and Mineral Research 1995;10:1289-93.

38. Abbasi M, Hasani S, Sheikholeslami H, Alizadeh S, Rashvand Z, Yazdi Z, et al. Association between Vitamin D Receptor APA1 AND TAQ1 genes polymorphisms and osteoporosis in postmenopuasal wemen. The Journal of Qazvin University of Medical Sciences 2012:4-10.

39. Mohammadi Z, Fayyazbakhsh F, Ebrahimi M, Amoli MM, Khashayar P, Dini M, et al. Association between vitamin D receptor gene polymorphisms (Fok1 and Bsm1) and osteoporosis: a systematic review. Journal of Diabetes & Metabolic Disorders 2014;13:98.

40. Bhanushali AA, Lajpal N, Kulkarni SS, Chavan SS, Bagadi SS, Das BR. Frequency of fokl and taqI polymorphism of vitamin D receptor gene in Indian population and its association with 25-hydroxyvitamin D levels. Indian J Hum Genet. 2009 Sep-Dec; 15(3): 108–113.

41. Falchetti A, Sferrazza C, Cepollaro C, Gozzini A, Del Monte F, Masi L, et al. FokI polymorphism of the vitamin D receptor gene correlates with parameters of bone mass and turnover in a female population of the Italian island of Lampedusa. Calcif Tissue Int 2007, 80:15–20.

42. Quesada JM1, Casado A, Díaz C, Barrios L, Cuenca-Acevedo R, Dorado G. Allele-frequency determination of BsmI and FokI polymorphisms of the VDR gene by quantitative real-time PCR (QRT-PCR) in pooled genomic DNA samples. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):209-14.

43. Khatkhatay MI. Genetic factors contributing to osteoporosis: Study of vitamin D receptor polymorphism and estrogen receptor gene in Indian population. Hum Mol Genet 2004;15:1633–9.

44. Eccleshall TR, Garnero P, Gross C, Delmas PD, Feldman D. Lack of correlation between start codon polymorphism of VDR gene and bone mineral density in postmenopausal French women: the OFELY study. J Bone Miner Res 1998; 13(1):31–5.

45. Hossein-Nezhad A, Ahangari G, Behzadi H, Maghbooli Z, Larijani B. Vitamin D receptor gene polymorphism may predict response to vitamin D intake and bone turnover. Daru 2009, 17:13–19.